Verve Therapeutics Inc VERV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 07/30/21 EDT
59.43quote price arrow up+0.96 (+1.64%)
Volume
179,380
52 week range
29.50 - 73.80

...

Loading . . .
  • Open59.11
  • Day High60.50
  • Day Low58.00
  • Prev Close58.47
  • 52 Week High73.80
  • 52 Week High Date06/30/21
  • 52 Week Low29.50
  • 52 Week Low Date06/17/21

Key Stats

  • Market Cap2.604B
  • Shares Out43.82M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open59.11
  • Day High60.50
  • Day Low58.00
  • Prev Close58.47
  • 52 Week High73.80
  • 52 Week High Date06/30/21
  • 52 Week Low29.50
  • 52 Week Low Date06/17/21
  • Market Cap2.604B
  • Shares Out43.82M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.16
  • P/E (TTM)-51.35
  • Fwd P/E (NTM)-26.50
  • EBITDA (MRQ)-45.862M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Verve Therapeutics Inc

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9...
Burt Adelman M.D.
Chairman
Sekar Kathiresan M.D.
Chief Executive Officer
Andrew Ashe J.D.
President
Address
500 Technology Square
Cambridge, MA
02139
United States